← Back to Search

Antiplatelet Agent

EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid) for Coronary Artery Disease

Phase 4
Waitlist Available
Research Sponsored by LifeBridge Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Drug Has Already Been Approved
Pivotal Trial
Approved for 20 Other Conditions
No Placebo-Only Group

Summary

This trial tests a special type of aspirin and a blood thinner on patients already using aspirin to see if it better prevents blood clots and reduces inflammation. Aspirin has been widely studied for its effectiveness in preventing cardiovascular events, with several studies supporting its use.

Eligible Conditions
  • Coronary Artery Disease
  • Peripheral Arterial Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Relative Difference in maximal ADP-induced Platelet Aggregation
Secondary study objectives
Relative differences in TF-thrombin-induced platelet aggregation
Relative differences in alpha- thrombin-induced platelet aggregation
Relative differences in endogenous thrombin potential
+6 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)Experimental Treatment2 Interventions
Group II: EC aspirin (81mg qd)Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban
FDA approved
Acetylsalicylic acid
FDA approved

Find a Location

Who is running the clinical trial?

Janssen Scientific Affairs, LLCIndustry Sponsor
164 Previous Clinical Trials
579,943 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
483 Patients Enrolled for Coronary Artery Disease
LifeBridge HealthLead Sponsor
28 Previous Clinical Trials
4,338 Total Patients Enrolled
8 Trials studying Coronary Artery Disease
2,737 Patients Enrolled for Coronary Artery Disease
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top